2,794 Becton, Dickinson and Company $BDX Shares Acquired by Quadrant Capital Group LLC

Quadrant Capital Group LLC lifted its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 34.0% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 11,015 shares of the medical instruments supplier’s stock after acquiring an additional 2,794 shares during the period. Quadrant Capital Group LLC’s holdings in Becton, Dickinson and Company were worth $1,972,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the business. Capstone Capital Management Ltd purchased a new stake in Becton, Dickinson and Company during the 3rd quarter worth approximately $791,000. Pinnacle Associates Ltd. raised its holdings in shares of Becton, Dickinson and Company by 12.2% in the third quarter. Pinnacle Associates Ltd. now owns 25,922 shares of the medical instruments supplier’s stock worth $4,640,000 after buying an additional 2,811 shares during the last quarter. Nisa Investment Advisors LLC raised its holdings in shares of Becton, Dickinson and Company by 18.9% in the third quarter. Nisa Investment Advisors LLC now owns 80,374 shares of the medical instruments supplier’s stock worth $14,387,000 after buying an additional 12,798 shares during the last quarter. Integrated Advisors Network LLC acquired a new stake in shares of Becton, Dickinson and Company during the third quarter worth $312,000. Finally, Robeco Institutional Asset Management B.V. lifted its stake in shares of Becton, Dickinson and Company by 271.8% during the third quarter. Robeco Institutional Asset Management B.V. now owns 159,520 shares of the medical instruments supplier’s stock worth $28,554,000 after buying an additional 116,612 shares during the period. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Wall Street Analyst Weigh In

BDX has been the topic of a number of research analyst reports. Evercore set a $180.00 price objective on shares of Becton, Dickinson and Company in a report on Monday, July 6th. Stifel Nicolaus set a $195.00 target price on Becton, Dickinson and Company in a research note on Friday, August 7th. Citigroup reaffirmed a “buy” rating on shares of Becton, Dickinson and Company in a research report on Thursday, August 13th. Wolfe Research began coverage on Becton, Dickinson and Company in a research note on Tuesday. They set an “outperform” rating on the stock. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $210.00 price objective on shares of Becton, Dickinson and Company in a report on Thursday, August 6th. Eight investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $185.07.

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX opened at $200.21 on Friday. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51. The stock has a market capitalization of $55.16 billion, a price-to-earnings ratio of 60.30, a PEG ratio of 13.10 and a beta of 0.21. The firm’s 50 day simple moving average is $185.10 and its 200-day simple moving average is $164.86. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $200.47.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The firm had revenue of $4.98 billion during the quarter, compared to analysts’ expectations of $4.89 billion. During the same period in the previous year, the business posted $3.68 EPS. The business’s revenue was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Analysts expect that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th were issued a $1.05 dividend. The ex-dividend date of this dividend was Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a yield of 2.1%. Becton, Dickinson and Company’s payout ratio is presently 126.51%.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, CEO Thomas Polen, Jr. sold 4,152 shares of the company’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $185.00, for a total value of $768,120.00. Following the completion of the transaction, the chief executive officer owned 110,163 shares in the company, valued at approximately $20,380,155. This represents a 3.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total transaction of $440,887.92. Following the sale, the executive vice president directly owned 14,856 shares in the company, valued at approximately $2,686,559.04. The trade was a 14.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 6,906 shares of company stock valued at $1,265,855. Corporate insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.